Over-the-Counter Agents for the Treatment of Occasional Disturbed Sleep or Transient Insomnia

缬草 耐受性 医学 失眠症 唑吡坦 安慰剂 苯海拉明 随机对照试验 临床试验 睡眠障碍 药理学 内科学 替代医学 不利影响 组胺 病理
作者
Larry Culpepper,Mark A. Wingertzahn
出处
期刊:The primary care companion for CNS disorders [Physicians Postgraduate Press, Inc.]
被引量:46
标识
DOI:10.4088/pcc.15r01798
摘要

To investigate the level of evidence supporting the use of common over-the-counter (OTC) agents (diphenhydramine, doxylamine, melatonin, and valerian) for occasional disturbed sleep or insomnia.A systematic review of the literature was conducted on July 31, 2014, using MEDLINE (PubMed) and the search terms (insomnia OR sleep) AND (over*the*counter OR OTC OR non*prescription OR antihistamine OR doxylamine OR diphenhydramine OR melatonin OR valerian) with the filters English, human, and clinical trials.Identified publications (from 2003 to July 31, 2014, following previous published literature reviews) that met the inclusion criteria were selected. The criteria included randomized placebo-controlled clinical studies that utilized overnight objective (polysomnography) or next-day participant-reported sleep-related endpoints and that were conducted in healthy participants with or without occasional disturbed sleep or diagnosed insomnia.Measures of efficacy and tolerability were summarized for each study individually and grouped according to OTC agent: H1 antagonists or antihistamines (3 studies, diphenhydramine), melatonin (8), and valerian or valerian/hops (7). Of the 3 sleep agents, studies conducted with melatonin, especially prolonged-release formulations in older individuals with diagnosed insomnia, demonstrated the most consistent beneficial effects (vs placebo) on sleep measures, specifically sleep onset and sleep quality, with favorable tolerability. In contrast, the clinical trial data for diphenhydramine, immediate-release melatonin, and valerian suggested limited beneficial effects.A review of randomized controlled studies over the past 12 years suggests commonly used OTC sleep-aid agents, especially diphenhydamine and valerian, lack robust clinical evidence supporting efficacy and safety.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
艾琳克斯完成签到 ,获得积分10
2秒前
啊啊发布了新的文献求助200
4秒前
星辰大海应助kyJYbs采纳,获得10
6秒前
咕咕风完成签到,获得积分10
7秒前
8秒前
木火应助初芷伊采纳,获得20
8秒前
木耳完成签到,获得积分10
10秒前
动漫大师发布了新的文献求助20
11秒前
求知者发布了新的文献求助10
12秒前
BBB完成签到,获得积分10
13秒前
斯文败类应助小皮不皮采纳,获得10
13秒前
虎嗅蔷薇关注了科研通微信公众号
14秒前
xz完成签到 ,获得积分10
14秒前
眼睛大迎波完成签到,获得积分10
15秒前
斯文败类应助机灵一兰采纳,获得10
15秒前
在水一方应助毛毛妈采纳,获得10
22秒前
岩下松风完成签到,获得积分10
23秒前
一个完成签到,获得积分10
23秒前
科研通AI2S应助GEeZiii采纳,获得10
24秒前
27秒前
28秒前
田様应助青椒采纳,获得10
30秒前
清爽幻竹完成签到,获得积分10
31秒前
32秒前
zishanchun完成签到,获得积分10
32秒前
虎嗅蔷薇发布了新的文献求助10
32秒前
33秒前
35秒前
35秒前
35秒前
杨甜心发布了新的文献求助10
39秒前
39秒前
ws发布了新的文献求助10
40秒前
40秒前
42秒前
酷波er应助小样采纳,获得20
43秒前
宁千凡发布了新的文献求助10
43秒前
majm应助啊啊采纳,获得10
45秒前
zzy完成签到,获得积分20
46秒前
火焰迷踪完成签到,获得积分10
47秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
T/CAB 0344-2024 重组人源化胶原蛋白内毒素去除方法 1000
Maneuvering of a Damaged Navy Combatant 650
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3775727
求助须知:如何正确求助?哪些是违规求助? 3321329
关于积分的说明 10204919
捐赠科研通 3036310
什么是DOI,文献DOI怎么找? 1666031
邀请新用户注册赠送积分活动 797258
科研通“疑难数据库(出版商)”最低求助积分说明 757783